Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.